GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » ROC (Joel Greenblatt) %

IN8bio (IN8bio) ROC (Joel Greenblatt) % : -379.52% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IN8bio ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. IN8bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -379.52%.

The historical rank and industry rank for IN8bio's ROC (Joel Greenblatt) % or its related term are showing as below:

INAB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3720.43   Med: -649.42   Max: -260
Current: -322.4

During the past 6 years, IN8bio's highest ROC (Joel Greenblatt) % was -260.00%. The lowest was -3720.43%. And the median was -649.42%.

INAB's ROC (Joel Greenblatt) % is ranked better than
50.45% of 1459 companies
in the Biotechnology industry
Industry Median: -333.95 vs INAB: -322.40

IN8bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 7.70% per year.


IN8bio ROC (Joel Greenblatt) % Historical Data

The historical data trend for IN8bio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio ROC (Joel Greenblatt) % Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -947.80 -3,720.43 -875.07 -423.76 -321.52

IN8bio Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -283.35 -295.23 -292.39 -347.91 -379.52

Competitive Comparison of IN8bio's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, IN8bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IN8bio's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where IN8bio's ROC (Joel Greenblatt) % falls into.



IN8bio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.343) - (2.206 + 0 + 1.673)
=-0.536

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.74) - (1.828 + 0 + 0.48)
=0.432

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of IN8bio for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-34.58/( ( (8.573 + max(-0.536, 0)) + (9.218 + max(0.432, 0)) )/ 2 )
=-34.58/( ( 8.573 + 9.65 )/ 2 )
=-34.58/9.1115
=-379.52 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IN8bio  (NAS:INAB) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


IN8bio ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of IN8bio's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


IN8bio (IN8bio) Business Description

Traded in Other Exchanges
Address
350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
Executives
Jeremy R. Graff director C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall officer: Chief Financial Officer C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho director, officer: President, CEO and CFO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l. director, 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc 10 percent owner 10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb officer: EVP and CSO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami officer: Chief Medical Officer C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin officer: Chief Operating Officer IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118

IN8bio (IN8bio) Headlines

From GuruFocus

IN8bio to Present at the Cowen 43rd Annual Healthcare Conference

By sperokesalga sperokesalga 03-01-2023

IN8bio to Present at Biotech Showcase 2023 in San Francisco

By Stock market mentor Stock market mentor 01-03-2023